1-anilino-8-naphthalenesulfonate has been researched along with Abdominal Obesity in 10 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet." | 9.15 | Pragmatic study of orlistat 60 mg on abdominal obesity. ( Beaver, JD; Bell, JD; Berk, ES; Delafont, B; Frost, G; Gambarota, G; Makwana, A; Matthews, PM; Mishra, RG; Newbould, R; Rao, AW; Schwartz, SM; Thomas, EL, 2011) |
| "It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet." | 5.15 | Pragmatic study of orlistat 60 mg on abdominal obesity. ( Beaver, JD; Bell, JD; Berk, ES; Delafont, B; Frost, G; Gambarota, G; Makwana, A; Matthews, PM; Mishra, RG; Newbould, R; Rao, AW; Schwartz, SM; Thomas, EL, 2011) |
| "In some patients with NAFLD, isolated steatosis can progress to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and hepatocellular carcinoma." | 2.61 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. ( Cusi, K; Häring, HU; Stefan, N, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are highly prevalent, affecting approximately one-third of the US population." | 2.58 | Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. ( Kim, D; Kim, WR; Touros, A, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D) and obesity are epidemiologically correlated with each other but the causal inter-relationships between them remain incompletely understood." | 1.56 | Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. ( Cai, D; Chen, YE; Dong, XC; Graham, S; Huang, M; Liu, W; Liu, Z; Pique-Regi, R; Wang, X; Willer, C; Zhang, Y, 2020) |
| "Visceral obesity is one of the risk factors for clinically relevant pancreatic fistula after pancreatic resection." | 1.51 | Clinical and experimental studies of intraperitoneal lipolysis and the development of clinically relevant pancreatic fistula after pancreatic surgery. ( Anazawa, T; Masui, T; Nagai, K; Nakano, K; Sato, A; Tabata, Y; Takaori, K; Uchida, Y; Uemoto, S; Yogo, A, 2019) |
| "Liver cirrhosis is a leading cause of death in Hispanics and Hispanics who live in South Texas have the highest incidence of liver cancer in the United States." | 1.43 | Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. ( Beretta, L; Fallon, MB; Fisher-Hoch, SP; Jiao, J; Lee, M; McCormick, JB; Pan, JJ; Rahbar, MH; Vatcheva, KP; Watt, GP, 2016) |
| "androgen deficiency) raises the risk for abdominal obesity in men." | 1.43 | Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. ( Hanaoka, R; Harada, N; Horiuchi, H; Inui, H; Kitakaze, T; Mitani, T; Yamaji, R, 2016) |
| " These negative associations between clinical risk factors and rs738409-G dosage were more prominent in non-NAFLD group compared to those in NAFLD group." | 1.42 | I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. ( Cho, B; Choi, HC; Hwang, KB; Kim, JI; Kong, SW; Kwon, H; Lee, IH; Park, JH; Prilutsky, D; Yun, JM, 2015) |
| "CT-defined fatty liver is common among men at risk for HIV infection and is associated with greater visceral adiposity, HOMA-IR, and PNPLA3 (rs738409)." | 1.40 | Risk factors for fatty liver in the Multicenter AIDS Cohort Study. ( Budoff, MJ; Kingsley, LA; Latanich, R; Palella, FJ; Post, WS; Price, JC; Seaberg, EC; Thio, CL; Witt, MD, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Zhang, Y | 1 |
| Graham, S | 1 |
| Wang, X | 1 |
| Cai, D | 1 |
| Huang, M | 1 |
| Pique-Regi, R | 1 |
| Dong, XC | 1 |
| Chen, YE | 1 |
| Willer, C | 1 |
| Liu, W | 1 |
| Kim, D | 1 |
| Touros, A | 1 |
| Kim, WR | 1 |
| Stefan, N | 1 |
| Häring, HU | 1 |
| Cusi, K | 1 |
| Xia, MF | 1 |
| Lin, HD | 1 |
| Chen, LY | 1 |
| Wu, L | 1 |
| Ma, H | 1 |
| Li, Q | 1 |
| Aleteng, Q | 1 |
| Hu, Y | 1 |
| He, WY | 1 |
| Gao, J | 1 |
| Bian, H | 1 |
| Li, XY | 1 |
| Gao, X | 1 |
| Uchida, Y | 1 |
| Masui, T | 1 |
| Nakano, K | 1 |
| Yogo, A | 1 |
| Sato, A | 1 |
| Nagai, K | 1 |
| Anazawa, T | 1 |
| Takaori, K | 1 |
| Tabata, Y | 1 |
| Uemoto, S | 1 |
| Price, JC | 1 |
| Seaberg, EC | 1 |
| Latanich, R | 1 |
| Budoff, MJ | 1 |
| Kingsley, LA | 1 |
| Palella, FJ | 1 |
| Witt, MD | 1 |
| Post, WS | 1 |
| Thio, CL | 1 |
| Park, JH | 1 |
| Cho, B | 1 |
| Kwon, H | 1 |
| Prilutsky, D | 1 |
| Yun, JM | 1 |
| Choi, HC | 1 |
| Hwang, KB | 1 |
| Lee, IH | 1 |
| Kim, JI | 1 |
| Kong, SW | 1 |
| Jiao, J | 1 |
| Watt, GP | 1 |
| Lee, M | 1 |
| Rahbar, MH | 1 |
| Vatcheva, KP | 1 |
| Pan, JJ | 1 |
| McCormick, JB | 1 |
| Fisher-Hoch, SP | 1 |
| Fallon, MB | 1 |
| Beretta, L | 1 |
| Harada, N | 1 |
| Hanaoka, R | 1 |
| Horiuchi, H | 1 |
| Kitakaze, T | 1 |
| Mitani, T | 1 |
| Inui, H | 1 |
| Yamaji, R | 1 |
| Thomas, EL | 1 |
| Makwana, A | 1 |
| Newbould, R | 1 |
| Rao, AW | 1 |
| Gambarota, G | 1 |
| Frost, G | 1 |
| Delafont, B | 1 |
| Mishra, RG | 1 |
| Matthews, PM | 1 |
| Berk, ES | 1 |
| Schwartz, SM | 1 |
| Bell, JD | 1 |
| Beaver, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| To Investigate the Role of Gut Microbiome in Androgen Deprivation Therapy Related Metabolic Changes in Prostate Cancer Patients[NCT04687709] | 50 participants (Anticipated) | Observational | 2021-01-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 1-anilino-8-naphthalenesulfonate and Abdominal Obesity
| Article | Year |
|---|---|
Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
Topics: Dyslipidemias; Humans; Hyperglycemia; Hypertension; Lipase; Membrane Proteins; Metabolic Syndrome; N | 2018 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Topics: Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Cardiovascular Diseases; Diabetes Mellit | 2019 |
1 trial available for 1-anilino-8-naphthalenesulfonate and Abdominal Obesity
| Article | Year |
|---|---|
Pragmatic study of orlistat 60 mg on abdominal obesity.
Topics: Abdominal Fat; Adiposity; Adult; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy; Di | 2011 |
7 other studies available for 1-anilino-8-naphthalenesulfonate and Abdominal Obesity
| Article | Year |
|---|---|
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.
Topics: Animals; Causality; Diabetes Mellitus, Type 2; Europe; Founder Effect; Genome-Wide Association Study | 2020 |
The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
Topics: Adipose Tissue; Aged; Anthropometry; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; F | 2019 |
Clinical and experimental studies of intraperitoneal lipolysis and the development of clinically relevant pancreatic fistula after pancreatic surgery.
Topics: Aged; Animals; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Humans; Intra-Abdominal F | 2019 |
Risk factors for fatty liver in the Multicenter AIDS Cohort Study.
Topics: Anti-HIV Agents; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Fatty Liver; Genetic | 2014 |
I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
Topics: Adult; Body Mass Index; Genetic Predisposition to Disease; Humans; Insulin Resistance; Lipase; Liver | 2015 |
Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity.
Topics: Cohort Studies; Female; Hispanic or Latino; Humans; Lipase; Liver Cirrhosis; Male; Membrane Proteins | 2016 |
Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice.
Topics: Adipose Tissue; Androgens; Animals; Anti-Bacterial Agents; Blood Glucose; Castration; Diet, High-Fat | 2016 |